China Hangzhou-based Leyi Biotech has completed an angel+ round of financing led by Leiyu Capital and Yuhang Jinkong Group, for the research and development and clinical trials of its core products.
From 2022 to 2023, Leyi Biotech has completed three rounds of financing, namely seed round, angel round and angel+ round, with a cumulative financing amount of tens of millions of RMB.
Leyi Biotech focuses on the research and innovation of cutting-edge biotechnology in the field of breath diagnostics, aiming to achieve rapid diagnosis and early screening of various diseases of the digestive system through human breath testing, and has one R&D centre, one data centre and two production bases in China.
Leyi Biotech’s Bioleya® Methane and Hydrogen Breathalyzer is a gas analysis technology based on flora metabolomics. By separating and measuring methane and hydrogen concentrations from human exhaled gas, it can accurately diagnose a wide range of digestive disorders such as flora imbalance, lactose intolerance, gastrointestinal motility, and pancreatic function.
The breathalyzer has been recognised by hundreds of domestic authoritative clinical experts from leading hospitals such as the Chinese PLA General Hospital, Peking Union Medical College Hospital, Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Zhongshan Hospital of Fudan University, the First Hospital of Sun Yat-sen University, and Huaxi Hospital of Sichuan University, and has been carried out in major hospitals for technical trainings and clinical applications.
The Post is Available in: English – 简体中文
English (UK) 
简体中文 
Deutsch 
Français 
Español 
Português 
日本語 
Italiano 
Nederlands 
